Physician

Thomas James Mulhearn, M.D.

According to 2025 Medicare claims, Thomas Mulhearn, M.D. (NPI: 1285789008) practices interventional cardiology in the Lake Charles, LA market, with the plurality of this provider's patient population coming from Calcasieu, LA. This provider's primary affiliated billing organization is IMPERIAL HEALTH, LLP (NPI: 1053352401; TIN: 721005645) and primary practice location at 70601-5724. Mulhearn is affiliated with the Aledade 35 Lagniappe MSSP Enhanced (ACO ID: A3899), participating under the MSSP model.

Mulhearn's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,193 traditional Medicare patients, billed 14,145 HCPCS/CPT codes, and received $1,137,742 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 5,903 prescription claims across 827 beneficiaries totaling $963,011 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 103 claims. Open Payments data shows 30 records totaling $697. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $176,741 to $963,011. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $40,480 to $13,098.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,513	8,620	$645,273
2016	2,678	16,088	$876,839
2017	2,579	24,656	$1,159,417
2018	2,400	21,348	$1,262,402
2019	2,599	15,144	$1,233,571
2020	2,274	15,613	$915,544
2021	2,991	28,366	$1,059,953
2022	3,074	26,184	$1,053,515
2023	2,216	13,654	$1,191,592
2024	2,193	14,145	$1,137,742

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	515	4,027	$176,741
2016	673	5,966	$322,076
2017	776	6,633	$437,051
2018	759	6,582	$463,469
2019	755	5,911	$533,921
2020	743	5,636	$612,349
2021	802	5,626	$660,171
2022	751	5,125	$734,496
2023	817	5,162	$870,152
2024	827	5,903	$963,011

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	112	$80,655
2016	N/R	204	$91,559
2017	N/R	47	$1,385
2018	N/R	30	$961
2019	N/R	25	$619
2020	N/R	22	$672
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	103	$13,504
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	739	778	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	916	1,413	$84
93356	Heart muscle strain imaging	478	491	$23
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	606	934	$12
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	544	861	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	582	27,888	$533,758
Xarelto	Rivaroxaban	200	7,672	$139,203
Entresto	Sacubitril/Valsartan	85	3,900	$84,991
Repatha Sureclick	Evolocumab	84	3,080	$59,661
Farxiga	Dapagliflozin Propanediol	34	1,440	$25,278

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	30	$697	Edwards Lifesciences Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas James Mulhearn, M.D.?

Tedicare shows public-source Medicare data for Thomas James Mulhearn, M.D. (NPI 1285789008), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas James Mulhearn, M.D. have ACO affiliation data?

Thomas James Mulhearn, M.D. is shown with ACO affiliation data for Aledade 35 Lagniappe MSSP Enhanced (MSSP, ACO ID A3899).

What billing organization is linked to Thomas James Mulhearn, M.D.?

Thomas James Mulhearn, M.D. is linked to IMPERIAL HEALTH, LLP (billing NPI 1053352401) in the available physician profile data.

Does Thomas James Mulhearn, M.D. have Open Payments data?

Thomas James Mulhearn, M.D. has 30 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.